Bora Opens US Office

Bora has announced the opening of its first North American office in Delaware, U.S.

The Asia-Pacific (APAC)-headquartered CDMO has established the office as part of its two-year plan to invest in the North American market.

“Opening an office on the East coast of the U.S., is a significant milestone for our organization and signals our continued commitment to the region,” Bobby Sheng, CEO at Bora Pharmaceuticals, said. “The office is one phase of our expansion plans, as we continue to explore acquisition opportunities in the market. It will not only support our own future growth strategy but also allows us to better support our growing client base, as companies across the U.S. continue to outsource their most complex oral solid dose (OSD) projects to Bora.”

Bora appointed its U.S. managing director of business development, Louis Weber, in late 2018 and he will lead the company’s growth strategy across North America and Europe.

Previously a senior director of business development at Halo Pharma (now acquired by Cambrex), Weber has almost 20 years’ experience in the pharmaceutical sector and sits at the forefront of Bora’s growth strategy.

“As an industry, we are seeing a rising demand for large scale manufacturing projects that have the same diverse and challenging requirements of niche drug products. This is what attracted me to Bora, as its sweet spot is providing complex dosage forms on a large commercial scale,” Weber said. “I am eager to build an ambitious team in North America that is inspired to continue delivering smart, solution-driven support for our clients and their complex MR projects.”

Bora offers a broad range of technologies across its multiple sites, from small scale R&D capabilities to large scale manufacturing services. The company also provides packaging, distribution, tech transfer, stability studies, and product life cycle management capabilities for clinical trial and commercial projects.

  • <<
  • >>